Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
Add more filters










Publication year range
1.
J Cosmet Sci ; 53(4): 209-18, 2002.
Article in English | MEDLINE | ID: mdl-12219247

ABSTRACT

Most of the slimming products already developed for cosmetic applications did not result from strategies that integrate whole lipolysis-regulating mechanisms. We thus focused our attention on a more complete integration of these mechanisms and we developed slimming liposomes (SLC) containing two micro-circulation activators, i.e., esculoside and Centella asiatica extracts, one phosphodiesterase inhibitor, i.e., caffeine, and one fatty acid-beta oxidation activator, i.e., L-carnitine. The validity of our approach was assessed through (a) in vitro tests demonstrating that SLC induced a dramatic increase in the cyclic adenosine monophosphate (cAMP) content in human adipocytes, with a subsequent rise in the nonesterified fatty acids (NEFA) content of human adipocyte incubation medium, and (b) in vivo studies showing that SLC could provide an actual potent slimming effect on human volunteers. Moreover, we give here, through binding experiments, the unambiguous demonstration that SLC is able to antagonize the alpha(2)-adrenergic receptor that is known to reduce intracellular AMPc content and, subsequently, to down-regulate lipolysis. This alpha(2)-adrenergic antagonism has never been reported for any component of SLC, and this work is the first demonstration of the alpha(2)-adrenergic antagonism of such a combination of active liposome compounds.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists , Lipolysis , Liposomes , Weight Loss/drug effects , Adipocytes/drug effects , Adipocytes/metabolism , Adrenergic alpha-Antagonists/pharmacology , Cyclic AMP/metabolism , In Vitro Techniques
2.
Neurosci Lett ; 301(3): 191-4, 2001 Apr 06.
Article in English | MEDLINE | ID: mdl-11257430

ABSTRACT

We looked for an interaction between etifoxine and the neurosteroid allopregnanolone at central gamma-aminobutyric acid (GABA(A)) receptors. Etifoxine (2 microM) did not affect the affinity of allopregnanolone (IC(50)=108 nM) for its site in preparations of Sprague-Dawley rat cerebral cortex membranes, as determined by the inhibition of [(35)S] t-butylbicyclophosphorothionate binding, a specific ligand of the GABA(A) receptor chloride channel site. Etifoxine and allopregnanolone were anticonvulsants, blocking the clonic convulsions induced by bicuculline (an antagonist of the GABA(A) receptor) in CD1 mice. A combination of subactive doses of the two compounds showed additive anticonvulsant effects. These results suggest that etifoxine and allopregnanolone bind to distinct putative recognition sites at or near the chloride channel site. Functionally, their binding may have an additive effect by enhancing GABA(A) inhibitory transmission.


Subject(s)
Anticonvulsants/pharmacology , Oxazines/pharmacology , Pregnanolone/pharmacology , Receptors, GABA-A/metabolism , Allosteric Site/drug effects , Animals , Bicuculline/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/metabolism , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Chloride Channels/chemistry , Chloride Channels/metabolism , Convulsants/metabolism , Convulsants/pharmacology , Drug Interactions , GABA Antagonists/pharmacology , Male , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/chemistry , Sulfur Radioisotopes
3.
J Steroid Biochem Mol Biol ; 75(2-3): 201-8, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11226836

ABSTRACT

The present study investigated the effect of genistein, daidzein and estradiol on in vitro rat uterine responsiveness to oxytocin (OT) and PGF(2)alpha or luprostiol (L). In a first experiment, animals were either sham-operated (SH; n=5), or ovariectomized (OVX; n=20) and orally treated for three months with either genistein (G; n=5; 10 microg/g BW/d) or daidzein (D; n=5; 10 microg/g BW/d) or 17 alpha-ethinylestradiol (E; n=5; 23 microg/kg BW/d) or untreated (OVX; n=5). At necropsy, the basal uterine tension was lower in OVX, G and D than in SH, the highest value being measured in E. Oxytocin (10(-12); 10(-11) M) or PGF(2)alpha (10(-12); 10(-9) M) induced an increase in SH, but not in OVX, E and G. In D, only the highest doses were efficient. In a second experiment, 20 intact animals were s.c. injected with either genistein (G; n=5; 10 microg/g BW) or daidzein (D; n=5; 10 microg/g BW) or estradiol benzoate (E; n=5; 23 microg/kg BW) or vehicle (C: controls; n=5), and killed 24 h later. In C and E, OT (10(-15) to 10(-10) M) or L (10(-12) to 10(-7) M) stimulated uterine contractile activity in a dose-dependent manner until a maximal level. On the opposite, in G and D, contractile agents (except the highest luprostiol doses) did not stimulate myometrium contractions. Moreover, radioligand binding assays showed that genistein or daidzein inhibited the specific binding of [(3)H] estradiol to the calf uterus estrogen receptor (ER). Therefore, it could be postulated that both genistein and daidzein might bind to the rat uterus ER, inducing either anti-estrogenic or very weak estrogenic effects (depending on the experimental conditions) on in vitro uterine responsiveness to OT and PGF(2)alpha or luprostiol.


Subject(s)
Enzyme Inhibitors/pharmacology , Estrogens, Non-Steroidal/pharmacology , Genistein/pharmacology , Isoflavones/pharmacology , Uterine Contraction/drug effects , Uterus/drug effects , Animals , Dinoprost/pharmacology , Enzyme Inhibitors/administration & dosage , Estradiol/analogs & derivatives , Estradiol/pharmacology , Estrogens, Non-Steroidal/administration & dosage , Female , Genistein/administration & dosage , In Vitro Techniques , Isoflavones/administration & dosage , Organ Size , Ovariectomy , Oxytocics/pharmacology , Oxytocin/pharmacology , Prostaglandins F, Synthetic/pharmacology , Random Allocation , Rats , Rats, Wistar , Receptors, Estrogen/metabolism , Uterus/anatomy & histology , Uterus/physiology
4.
Pharmacol Res ; 38(2): 111-7, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9721598

ABSTRACT

The interaction of Otilonium bromide (OB) with binding sites for 63 different receptors and ion channels in appropriate preparations has been investigated. Experiments were also performed in rat colon, the preferred tissue for OB 'in vivo' uptake after oral administration. Among the receptors investigated OB binds with sub microM affinity to muscarinic M1, M2, M4, M5 and PAF receptors and with microM affinity to the diltiazem binding site on L type Ca2+ channels. In the rat colon OB shows competitive interaction with the verapamil binding site on L type Ca2+ channels and with muscarinic M2 receptors with IC50 of 1020 and 1220 nM, respectively. These findings provide a molecular rationale to explain the spasmolytic action exerted by OB on intestinal smooth muscle. In particular, a combination of antimuscarinic and Ca2+ channel blocker properties seems to best account for the action of this compound.


Subject(s)
Colon/metabolism , Parasympatholytics/metabolism , Quaternary Ammonium Compounds/metabolism , Receptors, Muscarinic/metabolism , Receptors, Neurotransmitter/metabolism , Animals , Cell Line , Guinea Pigs , Humans , Rats , Receptors, Cell Surface/metabolism
5.
Neuropeptides ; 31(5): 449-58, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9413022

ABSTRACT

(R)-3-(1-[2-(4-benzoyl-2-(3,4-difluorophenyl)-morpholin-2-yl)- ethyl]-4-phenylpiperidin-4-yl)-1-dimethylurea (SR 144190) is a new non-peptide antagonist of tachykinin NK2 receptors. SR 144190 potently and selectively inhibited neurokinin A binding to NK2 receptors from various species, including humans. In in vitro functional assays, it was a potent, selective and competitive antagonist of NK2 receptors with apparent affinities (pA2 values) between 9.08 and 10.10. In vivo, SR 144190 blocked [Nle10]neurokinin A-(4-10)-induced bronchoconstriction in guinea pigs (ID50 = 21 micrograms kg-1 i.v. and 250 micrograms kg-1 i.d.) and [beta Ala8]neurokinin A-(4-10)-induced urinary bladder contraction in rats (ID50 = 11 micrograms kg-1 i.v. and 190 micrograms kg-1 i.d.). It prevented citric acid-induced cough and airway hyperresponsiveness to acetylcholine in guinea pigs (1 mg kg-1 i.p.) as well as castor oil-induced diarrhoea in rats (0.01-10 micrograms kg-1 s.c. or p.o). Finally, it blocked the turning behaviour induced by intrastriatal injections of [Nle10]neurokinin A-(4-10) in mice (ID50 = 3 micrograms kg-1 i.v. and 16 micrograms kg-1 p.o.).


Subject(s)
Methylurea Compounds/pharmacology , Morpholines/pharmacology , Receptors, Neurokinin-2/antagonists & inhibitors , Animals , Binding, Competitive , Biological Availability , Central Nervous System/drug effects , Central Nervous System/metabolism , Cricetinae , Digestive System/drug effects , Digestive System/metabolism , Female , Gerbillinae , Guinea Pigs , Humans , In Vitro Techniques , Male , Methylurea Compounds/chemistry , Methylurea Compounds/pharmacokinetics , Mice , Morpholines/chemistry , Morpholines/pharmacokinetics , Rats , Respiratory System/drug effects , Respiratory System/metabolism , Urinary Tract/drug effects , Urinary Tract/metabolism
6.
Eur J Pharmacol ; 314(1-2): 229-33, 1996 Oct 24.
Article in English | MEDLINE | ID: mdl-8957240

ABSTRACT

The dopamine D4 receptor is a potential target for novel antipsychotic drugs. Most available compounds with affinity for the dopamine D4 receptor also bind to dopamine D2 receptors. This report describe the affinity of the 5-HT2A receptor antagonist RP 62203 (fananserin) for the human dopamine D4 receptor. Fananserin displaces [3H]spiperone binding to recombinant human dopamine D4 receptors with a Ki of 2.93 nM. This compares with an affinity (Ki) of 0.37 nM for the rat 5-HT2A receptor and of 726 mM for the rat dopamine D2 receptor. [3H]Fananserin can be used to label the recombinant dopamine D4 receptor expressed in Chinese hamster ovary cells with a KD of 0.725 nM. Fananserin is, thus, the first compound to be reported that distinguishes between dopamine D4 and D2 receptors.


Subject(s)
Cyclic S-Oxides/metabolism , Naphthalenes/metabolism , Receptors, Dopamine D2/metabolism , Serotonin Antagonists/metabolism , Animals , Binding, Competitive , CHO Cells , Cricetinae , Humans , Male , Rats , Rats, Sprague-Dawley , Receptor, Serotonin, 5-HT2A , Receptors, Dopamine D4 , Receptors, Serotonin/metabolism
7.
Neuropharmacology ; 35(5): 589-93, 1996 May.
Article in English | MEDLINE | ID: mdl-8887966

ABSTRACT

The effects of subacute administration of the double noradrenaline and serotonin uptake inhibitor antidepressant, milnacipran, and the tricyclic antidepressant, imipramine, on radioligand binding to beta-adrenergic receptors and on beta-adrenergic agonist-stimulated adenylate cyclase activity, in the rat cerebral cortex, have been determined. Rats were injected intraperitoneally for 21 days with milnacipran (3, 10 or 30 mg/kg/day) or imipramine (10 mg/kg/day). The treatment with milnacipran up to 30 mg/kg/day did not modify either the maximum number of [3H]CGP-12177 binding sites (Bmax) or the equilibrium dissociation constant (Kd). On the other hand, treatment of the rats with 10 mg/kg/day imipramine induced a decrease (27%) in Bmax [3H]CGP-12177 binding sites without affecting the Kd value. Furthermore, milnacipran did not affect the stimulation of cAMP production induced by either 30 microM isoprenaline, 10 microM GTP gamma S or 10 microM forskolin. Under similar conditions, treatment with imipramine reduced by 70% the isoprenaline-induced stimulation of cAMP production without affecting that induced by either GTP gamma S or forskolin. These results demonstrate that, unlike imipramine, subacute administration of milnacipran does not produce any change in beta-adrenoceptor sensitivity in the rat brain cortex.


Subject(s)
Adenylyl Cyclases/drug effects , Antidepressive Agents/pharmacology , Cerebral Cortex/drug effects , Cyclopropanes/pharmacology , Animals , Dose-Response Relationship, Drug , Isoproterenol/pharmacology , Male , Milnacipran , Rats , Rats, Wistar
8.
FEBS Lett ; 362(2): 192-6, 1995 Apr 03.
Article in English | MEDLINE | ID: mdl-7720871

ABSTRACT

An orally-active antagonist of neuropeptide Y (NPY) Y1 receptors, SR 120819A, has been characterized. This compound displays highly selective and competitive affinity for rat, guinea-pig and human (Ki = 15 nM) NPY Y1 receptors. In vitro, SR 120819A blocks the inhibitory effect of NPY on adenylyl cyclase activity in human SK-N-MC cells and that of the selective Y1 agonist, [Leu31,Pro34]NPY, on rabbit vas deferens contraction (pA2 = 7.20 +/- 0.07). In vivo, by intravenous route, this compound acts as an antagonist in anesthetized guinea-pigs and, notably, after oral administration, SR 120819A counteracts the pressor response of [Leu31,Pro34]NPY (5 micrograms/kg i.v.) with a long duration of action (> 4 h at 5 mg/kg p.o.). Thus, SR 120819A is the first orally-effective NPY Y1 receptor antagonist yet described. It could be a useful tool for exploring the role of NPY and the therapeutic relevance of an antagonist at NPY Y1 receptors.


Subject(s)
Naphthalenes/pharmacology , Phenylalanine/analogs & derivatives , Pyrrolidines , Receptors, Neuropeptide Y/antagonists & inhibitors , Adenylyl Cyclases/metabolism , Animals , Binding, Competitive , Blood Pressure/drug effects , Cell Line , Electric Stimulation , Guinea Pigs , Humans , Kinetics , Male , Muscle Contraction/drug effects , Naphthalenes/chemistry , Naphthalenes/metabolism , Neuropeptide Y/antagonists & inhibitors , Neuropeptide Y/pharmacology , Phenylalanine/chemistry , Phenylalanine/metabolism , Phenylalanine/pharmacology , Rabbits , Rats , Vas Deferens/physiology
9.
Life Sci ; 56(1): PL27-32, 1995.
Article in English | MEDLINE | ID: mdl-7830490

ABSTRACT

SR 142801 is the first potent and selective non-peptide antagonist of the tachykinin NK3 receptor. It inhibited [MePhe7]NKB binding to its receptor from various species, including humans. SR 142801 was a competitive antagonist of [MePhe7]NKB-mediated contractions of guinea-pig ileum and inhibited the acetylcholine release following the activation of the guinea-pig ileum tachykinin NK3 receptor. In vivo, SR 142801 potently inhibited the turning behaviour induced by intrastriatal injection of senktide in gerbils, and appears as a powerful tool for investigation of the physiological and pathological role of NKB and its NK3 receptor.


Subject(s)
Piperidines/pharmacology , Receptors, Neurokinin-3/antagonists & inhibitors , Animals , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Gerbillinae , Guinea Pigs , In Vitro Techniques , Neurokinin B/analogs & derivatives , Neurokinin B/antagonists & inhibitors , Neurokinin B/metabolism , Rats , Vasoconstriction/drug effects
10.
Br J Pharmacol ; 113(2): 389-94, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7834189

ABSTRACT

1. Binding of the specific bradykinin B1 receptor agonist, [3H]-des-Arg10-kallidin (-KD) was investigated in smooth muscle cells (SMC) isolated from rabbit mesenteric arteries (RMA). 2. [3H]-des-Arg10-KD specifically bound to interleukin-1 (IL-1)-treated RMA-SMC in a saturable fashion with an equilibrium dissociation constant (KD) of 0.3-0.5 nM. The number of binding sites per cell was 20,000-35,000. Kinins inhibited [3H]-des-Arg10-KD binding to RMA-SMC with an order of potency very similar to that observed in typical B1 specific bioassays: des-Arg9-bradykinin (BK) approximately KD >> BK. Furthermore, the B1 receptor antagonist [Leu8]des-Arg9-BK inhibited [3H]-des-Arg10-KD binding with an IC50 of 43 nM as expected for its effect at B1 receptors. The B2 receptor antagonists, NPC 567 and Hoe 140 only affected [3H]-des-Arg10-KD binding at very high concentrations (IC50 = 0.8 microM and IC50 > 10 microM, respectively). 3. Des-Arg9-BK (B1 agonist) and [Hyp3]Tyr(Me)8-BK (B2 agonist) did not induce prostacyclin (PGI2) production by RMA-SMC. Lipopolysaccharide (LPS) treatment of the cells did not affect the B1 agonist response whereas IL-1 beta treatment produced a 7 fold increase in des-Arg9-BK-stimulated PGI2 production. IL-1 beta also stimulated the response to B2 agonists. 4. Des-Arg9-BK-induced PGI2 secretion in IL-1-primed RMA-SMC was mediated by B1 receptors since it was inhibited by [Leu8]des-Arg9-BK (IC50 = 56-73 nM) but not by Hoe 140. High concentrations of NPC 567 (IC5o = 2.4 micro M) were required to inhibit PGI2 production induced by B1 agonists.5. IL- 1-treated RMA-SMC displayed a 5 fold increase in the number of B1 receptors without modification of the affinity constant, thus establishing a possible relationship between the receptor density and the IL-i-primed B1 response.6. LPS treatment of the cells induced a 4 fold increase in B1 receptor number without modifying PGI2 secretion. This observation suggests that IL-1 but not LPS, in addition to increase in the number of receptors, signals the cell to permit the coupling of B1 receptors to the PLA2/cyclo-oxygenase pathway.


Subject(s)
Epoprostenol/biosynthesis , Interleukin-1/pharmacology , Kallidin/analogs & derivatives , Muscle, Smooth, Vascular/metabolism , Receptors, Bradykinin/metabolism , Up-Regulation/drug effects , Animals , Bradykinin Receptor Antagonists , In Vitro Techniques , Kallidin/pharmacokinetics , Lipopolysaccharides/pharmacology , Mesenteric Arteries/cytology , Mesenteric Arteries/drug effects , Mesenteric Arteries/metabolism , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Nitric Oxide/physiology , Rabbits , Receptors, Bradykinin/agonists , Signal Transduction/drug effects
11.
FEBS Lett ; 350(2-3): 240-4, 1994 Aug 22.
Article in English | MEDLINE | ID: mdl-8070571

ABSTRACT

SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes. After intraperitoneal or oral administration SR141716A antagonises classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.


Subject(s)
Brain/drug effects , Cannabinoids/pharmacology , Piperidines/pharmacology , Pyrazoles/pharmacology , Receptors, Drug/antagonists & inhibitors , Animals , Benzoxazines , Binding, Competitive , Biological Assay , Cell Membrane/metabolism , Cyclohexanols/metabolism , In Vitro Techniques , Mice , Morpholines/pharmacology , Naphthalenes/pharmacology , Rats , Receptors, Cannabinoid , Rimonabant
12.
Eur J Pharmacol ; 250(3): 403-13, 1993 Dec 21.
Article in English | MEDLINE | ID: mdl-7509286

ABSTRACT

(S)1-(2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)pip eridin-3- yl]ethyl)-4-phenyl-1-azoniabicyclo[2.2.2]octane chloride (SR140333) is a new non-peptide antagonist of tachykinin NK1 receptors. SR140333 potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans. In vitro, it was a potent antagonist in functional assays for NK1 receptors such as [Sar9,Met(O2)11]substance P-induced endothelium-dependent relaxation of rabbit pulmonary artery and contraction of guinea-pig ileum. Up to 1 microM, it had no effect in bioassays for NK2 ([beta Ala8]neurokinin A-induced contraction of endothelium-deprived rabbit pulmonary artery) and NK3 ([MePhe7]neurokinin B-induced contraction of rat portal vein) receptors. The antagonism exerted by SR140333 toward NK1 receptors was apparently non-competitive, with pD2' values (antagonism potency evaluated by the negative logarithm of the molar concentration of antagonist that produces a 50% reduction of the maximal response to the agonist) between 9.65 and 10.16 in the different assays. SR140333 also blocked in vitro [Sar9,Met(O2)11]substance P-induced release of acetylcholine from rat striatum. In vivo, SR140333 exerted highly potent antagonism toward [Sar9,Met(O2)11]substance P-induced hypotension in dogs (ED50 = 3 micrograms/kg i.v.), bronchoconstriction in guinea-pig (ED50 = 42 micrograms/kg i.v.) and plasma extravasation in rats (ED50 = 7 micrograms/kg i.v.). Finally, it also blocked the activation of rat thalamic neurons after nociceptive stimulation (ED50 = 0.2 micrograms/kg i.v.).


Subject(s)
Neurokinin-1 Receptor Antagonists , Piperidines/pharmacology , Quinuclidines/pharmacology , Animals , Brain/drug effects , Brain/metabolism , Bronchoconstriction/drug effects , Capillary Permeability/drug effects , Cell Line , Dogs , Endothelium, Vascular/physiology , Guinea Pigs , Humans , Hypotension/chemically induced , Hypotension/drug therapy , Male , Muscle Relaxation/drug effects , Muscle, Smooth/drug effects , Neurons/drug effects , Rabbits , Rats , Rats, Sprague-Dawley , Receptors, Neurokinin-1/metabolism , Substance P/analogs & derivatives , Substance P/metabolism , Substance P/pharmacology , Tumor Cells, Cultured
14.
Circ Shock ; 40(2): 139-43, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8508518

ABSTRACT

During septic shock, arterial smooth muscle is thought to be hyporeactive to vasoconstrictors. This hyporeactivity, however, seems to be different from one vascular bed to another. Interleukin-1 (IL-1), which is released during septic shock, might play a role in the different regional vascular responses to norepinephrine. Thus, the aim of the present study was to examine in vitro the effect of IL-1 on the response to norepinephrine of arteries isolated from different territories in the rabbit. Three types of responses were identified: IL-1 decreased NE-induced contraction by 54% in aorta, 42% in carotid artery, 54% in pulmonary artery, and 18% in renal artery; and IL-1 was devoid of significant effect in hepatic and mesenteric arteries; and IL-1 increased NE-induced contraction by 25% in femoral arteries. In conclusion, IL-1 might contribute to the regional blood flow abnormalities during septic shock.


Subject(s)
Arteries/physiology , Interleukin-1/pharmacology , Norepinephrine/pharmacology , Animals , Aorta/drug effects , Aorta/physiology , Arteries/drug effects , Carotid Arteries/drug effects , Carotid Arteries/physiology , Femoral Artery/drug effects , Femoral Artery/physiology , Male , Muscle Contraction/drug effects , Pulmonary Artery/drug effects , Pulmonary Artery/physiology , Rabbits , Renal Artery/drug effects , Renal Artery/physiology
15.
Eur J Pharmacol ; 232(1): 13-9, 1993 Feb 23.
Article in English | MEDLINE | ID: mdl-7681406

ABSTRACT

SR 27897 is a new non-peptide antagonist of CCKA receptors: 1-[[2-(4-(2-chlorophenyl)thiazol-2-yl)aminocarbonyl] indolyl] acetic acid. This compound is a potent ligand for CCKA binding sites (rat pancreatic membranes, Ki = 0.2 nM) and is highly selective (CCKB and gastrin/CCKA IC50 ratios of 800 and 5000 respectively). In vitro, it is a competitive antagonist of cholecystokinin (CCK)-stimulated amylase release in isolated rat pancreatic acini (pA2 = 7.50) and of CCK-induced guinea pig gall bladder contractions (pA2 = 9.57). In in vivo gastrointestinal models, SR 27897 confirmed the potency obtained in vitro: at 1 mg/kg (i.v.) it completely reversed the CCK-induced amylase secretion, at 3 micrograms/kg (p.o.) it antagonized by 50% the CCK-induced inhibition of gastric emptying of a charcoal meal in mice, and 72 micrograms/kg (p.o.) was the median effective dose for inhibiting CCK-induced gall bladder emptying in mice. SR 27897 was also very active (ED50 = 27 micrograms/kg p.o.) in the gall bladder emptying protocol with egg yolk as an inducer of endogenous CCK release. SR 27897 had a long-lasting action in all the experiments, with no differences between oral and intravenous routes of administration. SR 27897 was more or less effective than L-364,718, depending on the model and the species. Both compounds increased the gall bladder volume of fasting mice, but the effect of SR 27897 was 10 times lower than that of L-364,718. In summary, SR 27897 is a selective antagonist of CCKA receptors, is highly potent in animal models whatever the route of administration and has a long duration of action.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Indoleacetic Acids/pharmacology , Receptors, Cholecystokinin/antagonists & inhibitors , Thiazoles/pharmacology , Administration, Oral , Amylases/drug effects , Animals , Benzodiazepinones/pharmacology , Binding, Competitive , Cholecystokinin/antagonists & inhibitors , Cholecystokinin/metabolism , Devazepide , Dose-Response Relationship, Drug , Female , Gallbladder/drug effects , Gastric Emptying/drug effects , Gastrins/drug effects , Guinea Pigs , In Vitro Techniques , Injections, Intravenous , Male , Mice , Pancreas/drug effects , Radioligand Assay , Rats , Rats, Wistar , Stomach/drug effects
16.
J Pharmacol Exp Ther ; 262(2): 759-68, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1501121

ABSTRACT

A new potent, selective and p.o. active serotonergic [5-hydroxytryptamine (5-HT2)] receptor antagonist, SR 46349B [trans, 4-([3Z)3-(2-dimethylaminoethyl)oxyimino-3(2-flurophenyl++ +)propen-1-yl]phenol hemifumarate) has been characterized by a series of "in vitro" and "in vivo" methods. Based upon binding studies with 5-HT2 receptors in rat brain cortical membranes and blockade of 5-HT-induced contractions in isolated tissues (rabbit thoracic aorta, rat jugular vein, rat caudal artery, rat uterus and guinea pig trachea), SR 46349B showed high affinity for 5-HT2 receptors. Furthermore, SR 46349B displayed moderate affinity for the 5-HT1C receptor and had no affinity for the other 5-HT1 subclass (5-HT1A, 5-HT1B or 5-HT1D), dopamine (D1 or D2), "alpha" adrenergic (alpha-1 or alpha-2), sodium and calcium channel and histamine (H1) receptors. It did not interact with histamine (H1), alpha-1 adrenergic and 5-HT3 receptors in smooth muscle preparations. No inhibition of the uptake of norepinephrine, dopamine or 5-HT was seen. Based upon blockade of pressor responses to 5-HT in pithed rats and in vivo binding studies in mice, SR 46349B was found to be a potent and p.o. active 5-HT2 receptor antagonist with a relatively long duration of action. Behavioral experiments, including mescaline- and 5-hydroxytryptophan-induced head twitches and learned helplessness, as well as sleep-waking cycle and EEG spectral parameter studies, indicated that SR 46349B has a classical 5-HT2 psychopharmacological antagonist profile.


Subject(s)
Fluorobenzenes/pharmacology , Phenols/pharmacology , Serotonin Antagonists , Serotonin Antagonists/pharmacology , Animals , Brain/drug effects , Brain/metabolism , Electroencephalography , Escape Reaction/drug effects , Female , Guinea Pigs , In Vitro Techniques , Ketanserin/metabolism , Male , Muscle Contraction/drug effects , Rats , Rats, Inbred Strains , Receptors, Serotonin/metabolism , Serotonin Antagonists/metabolism , Sleep/drug effects
17.
Biochem Biophys Res Commun ; 184(3): 1418-24, 1992 May 15.
Article in English | MEDLINE | ID: mdl-1317173

ABSTRACT

SR 48968, a new non-peptide antagonist of NK2 receptors, has been tested in a variety of isolated smooth muscle preparations from rats, guinea pigs, rabbits, hamsters and men, in order to assess its selectivity for NK2 receptors as well as its competitivity and specificity. The compound has been found to be inactive as a stimulant or relaxant in all preparations but to exert a potent, competitive antagonism, particularly in tissues obtained from rabbits (pA2 9.8-10.3), guinea pigs (10.5), rats (9.4-9.6), men (9.36-9.6) and hamsters (7.45-8.6). SR 48968 is therefore more active on the NK2A than on the NK2B receptor subtype and the human receptor is close to the NK2A subtype. SR 48968 exerts an antagonism of the competitive type and is therefore suitable for receptor classification despite its slow reversibility in vitro. The sensitivity of NK2A receptors to SR 48968 is at least 1000 times higher than those of NK1 and NK3 receptors. The compound does not affect the effects of bradykinin, angiotensin or bombesin. Because of its activity in human tissues, its potency and long duration of action, SR 48968 is a new promising pharmacologic and possibly therapeutic agent.


Subject(s)
Benzamides/pharmacology , Isometric Contraction/drug effects , Muscle, Smooth, Vascular/physiology , Muscle, Smooth/physiology , Piperidines/pharmacology , Receptors, Neurotransmitter/antagonists & inhibitors , Animals , Cricetinae , Dose-Response Relationship, Drug , Guinea Pigs , Humans , In Vitro Techniques , Male , Mesocricetus , Muscle, Smooth/drug effects , Muscle, Smooth, Vascular/drug effects , Neurokinin A/antagonists & inhibitors , Neurokinin A/metabolism , Organ Specificity , Rabbits , Rats , Rats, Inbred Strains , Receptors, Neurokinin-2 , Receptors, Neurotransmitter/physiology , Species Specificity
18.
Life Sci ; 50(15): PL101-6, 1992.
Article in English | MEDLINE | ID: mdl-1313515

ABSTRACT

SR 48968 is a potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. SR 48968 selectively inhibited neurokinin A binding to its receptor and was a competitive antagonist of neurokinin A-mediated contraction of different isolated smooth muscle preparations from various species including human. In vivo, the compound inhibited the bronchoconstriction induced by neurokinin A in guinea pigs. SR 48968 can be used to study the physiological or pathological role of neurokinin A and may be useful in the treatment of neurokinin A-dependent pathology.


Subject(s)
Benzamides/pharmacology , Neurokinin A/antagonists & inhibitors , Piperidines , Receptors, Neurotransmitter/drug effects , Animals , Benzamides/chemistry , Binding, Competitive , Bronchoconstriction/drug effects , Cricetinae , Duodenum/metabolism , Intestinal Mucosa/metabolism , Rabbits , Rats , Receptors, Neurokinin-2 , Vasoconstriction/drug effects
19.
Biochem Biophys Res Commun ; 182(2): 733-9, 1992 Jan 31.
Article in English | MEDLINE | ID: mdl-1734880

ABSTRACT

Incubation of rabbit aortic rings with interleukin-1 (100 U/ml) in vitro led to a depressed contractile response to norepinephrine, whether the endothelium was present or not. In both cases norepinephrine-induced contraction was restored in the presence of NG-methyl-L-arginine (300 microM), an inhibitor of nitric oxide synthesis. In interleukin-1-treated rings precontracted with norepinephrine (1 microM), the relaxing response to acetylcholine was totally suppressed independently on the presence of endothelium. High concentrations of acetylcholine (greater than 1 microM) induced a slight contraction which was of lower amplitude than that obtained in control endothelium-denuded rings and was increased in the presence of NG-methyl-L-arginine. These results show that interleukin-1 (i) affects not only vascular contraction but also relaxation and (ii) involves both endothelial and non-endothelial factors. These observations suggest an impairment of the whole vascular reactivity during septic shock.


Subject(s)
Aorta, Thoracic/physiology , Interleukin-1/pharmacology , Muscle Contraction/drug effects , Muscle Relaxation/drug effects , Muscle, Smooth, Vascular/physiology , Acetylcholine/pharmacology , Animals , Aorta, Thoracic/drug effects , Arginine/analogs & derivatives , Arginine/pharmacology , Dose-Response Relationship, Drug , In Vitro Techniques , Male , Muscle, Smooth, Vascular/drug effects , Norepinephrine/pharmacology , Rabbits , Recombinant Proteins/pharmacology , omega-N-Methylarginine
20.
Eur J Pharmacol ; 199(1): 19-25, 1991 Jun 18.
Article in English | MEDLINE | ID: mdl-1680058

ABSTRACT

The pharmacological characterization of beta-adrenoceptor subtypes and the identification of two cell populations were investigated in isolated bovine mesenteric lymphatic vessels. The beta-adrenoceptor agonists isoprenaline, dobutamine and salbutamol concentration dependently decreased the amplitude and the frequency of spontaneous contractions and the amplitude of electrically induced contractions. The order of potency was isoprenaline greater than salbutamol greater than dobutamine. These effects were competitively antagonized by atenolol with pA2 values close to 7 with isoprenaline and dobutamine as agonists, and near 5.5 with salbutamol as the agonist. Noradrenaline concentration dependently reduced electrically induced contractions, an effect which was reversed to a slight enhancement after blockade of beta-adrenoceptors with propranolol (10(-6) M). These results confirmed the presence of postjunctional beta 1- and beta 2-adrenoceptor subtypes in lymphatic vessels and provide the first indication of the existence of two pharmacologically and functionally distinct cell populations, one of which exhibits pacemaker activity.


Subject(s)
Lymphatic System/drug effects , Muscle, Smooth, Vascular/drug effects , Receptors, Adrenergic, beta/drug effects , Adrenergic beta-Agonists/pharmacology , Adrenergic beta-Antagonists/pharmacology , Animals , Cattle , Electric Stimulation , In Vitro Techniques , Mesentery/physiology , Muscle Contraction/drug effects , Norepinephrine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...